Acurx Pharmaceuticals (ACXP) Operating Expenses (2020 - 2026)

Acurx Pharmaceuticals (ACXP) has reported Operating Expenses for 7 consecutive years, with $2.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 1.65% year-over-year to $2.3 million; the trailing twelve-month figure through Jun 2026 stood at $7.7 million (down 23.82% YoY), and the FY2025 full-year result was $8.1 million, down 42.7% from the prior year.
• Operating Expenses improved to $2.3 million in Q2 2026 per ACXP's latest filing, from $1.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $5.1 million in Q4 2023 and bottomed at $1.6 million in Q4 2025.
• Historically, Operating Expenses has averaged $2.9 million across 5 years, with a median of $2.8 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 81.11% in 2022, then slumped 50.28% in 2025.
• Over 5 years, Operating Expenses stood at $3.3 million in 2022, then soared by 56.86% to $5.1 million in 2023, then plunged by 45.38% to $2.8 million in 2024, then slumped by 42.12% to $1.6 million in 2025, then jumped by 42.68% to $2.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $2.3 million, $1.7 million, and $1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.